Regulatory Teva Receives FDA Approval of Denosumab Biosimilar and Filing Acceptances by FDA and EMA For Omalizumab Biosimilar Big Molecule WatchOn March 30, 2026, Teva Pharmaceutical Industries Ltd.RegulatoryRead full story pharminent April 9, 2026 (Last updated: April 9, 2026) Big Molecule Watch On March 30, 2026, Teva Pharmaceutical Industries Ltd. RegulatoryRead full story Post navigation Previous: Lilly launches GLP-1 pill, kicking off showdown with Novo NordiskNext: Precision Medicine in Early Oncology Trials: Biomarkers as Strategic Drivers Related Stories Regulatory Bayer’s Hyrnuo set for the NSCLC frontlines on accelerated FDA label expansion pharminent September 10, 2026 Regulatory HHS appoints permanent FDA CBER, CDER heads pharminent September 10, 2026 Regulatory FDA approves AstraZeneca’s Etcamah combo for advanced breast cancer pharminent September 7, 2026